Cerebrolysin: a porcine brain extract with more trial data than most approved drugs
Unusual in this reference for having too much evidence rather than too little — and for that evidence pointing in two directions depending on who assembled it. Both halves of that need saying.
Regulatory status. Approved drug in 50+ countries (EU, Russia, China, etc). NOT FDA approved in the US. Must be sourced internationally or through specialty compounding. That is the app’s own field, reproduced here rather than summarised. It means no regulator has reviewed a manufacturer’s evidence for identity, purity, potency or safety in people for this compound, so nothing below is a marketing claim about a product you can buy.
Purity, identity and concentration are therefore unverified by anyone but whoever made the vial. The storage rule in the fact box below is general practice for this formulation rather than a specification for a particular product: General handling practice for this formulation. Your supplier’s own insert or COA overrides anything here.
This page names no vendor, no clinic and no testing service, and there is no discount code anywhere on this site — the moment a page like this recommends where to buy, it stops being information.
- Also known as
- FPF-1070, CERE
- Class
- Neurological and cognitive
- Regulatory status
- Approved drug in 50+ countries (EU, Russia, China, etc). NOT FDA approved in the US. Must be sourced internationally or through specialty compounding.
- Before mixing
- Sealed powder tolerates room temperature in transit, but keep it refrigerated at 2–8 °C (36–46 °F) for anything beyond a few weeks, or frozen for months. Keep it dark — the carton it shipped in is doing a job.
- After mixing
- Once reconstituted with bacteriostatic water: refrigerate at 2–8 °C and use within about 28 days. The benzyl alcohol in bacteriostatic water is what buys that window — plain sterile water has no preservative, so a vial mixed with it should be treated as one sitting only. Kits are usually ten vials: only the one you mixed is on that 28-day clock — the sealed ones keep their own, much longer shelf life, so store them as powder, not as solution.
- What ruins it
- Do not freeze a reconstituted vial. Repeated freeze–thaw is one of the more reliable ways to degrade a peptide.
- Handling caveat
- General handling practice for this formulation. Your supplier’s own insert or COA overrides anything here.
What it actually is
Established clinical use Cerebrolysin is not a single molecule. It is a standardised enzymatic hydrolysate of porcine brain tissue: a mixture of low-molecular-weight peptides and free amino acids, produced to a manufacturing specification rather than synthesised to a formula. That makes it closer to a biological product than to the peptides elsewhere on this site, and it is the reason there is no half-life in the fact box — the app holds none, and a mixture does not have one.
Animal-only or theoretical The proposed mechanism is neurotrophic: the fragments are said to mimic the action of endogenous neurotrophic factors, promoting neuronal survival, synaptogenesis and plasticity after injury. That account is supported by animal and cell work. Whether a peptide mixture given intravenously reaches the brain in a form that does any of that in a human is the question the mechanism does not answer by itself.
It requires intramuscular or intravenous administration — there is no oral or intranasal route with systemic effect — and the courses described are daily for ten to twenty days, repeated. That is a clinical undertaking rather than a supplement schedule.
A large evidence base, and what independent review made of it
Off-label or community practice It is an approved medicine in dozens of countries and has been studied in well over a hundred clinical trials for acute ischaemic stroke, traumatic brain injury, vascular dementia and Alzheimer’s disease. By volume, that is more clinical investigation than almost anything else in this reference.
Independent systematic reviews have been considerably less positive than that volume suggests. Cochrane reviews of cerebrolysin in acute ischaemic stroke have not found evidence of benefit on death or dependence, and have raised concerns about the concentration of trials among investigators connected to the manufacturer and about reporting quality. Reviews in dementia have been similarly cautious. That is not the same as saying it does not work; it is saying that a large body of trials has not convinced reviewers who were not part of producing it.
The honest summary for a reader is that the evidence is voluminous, geographically and commercially concentrated, and unpersuasive to independent assessment. Anyone quoting the number of studies without quoting the reviews is telling half of it.
What that means for cognitive use in a healthy person
Every indication it is approved for involves a damaged brain — stroke, injury, dementia. Animal-only or theoretical Use for cognitive enhancement in a healthy adult is off-label everywhere it is approved and unstudied everywhere else. A neurotrophic agent plausibly has more to do where there is damage to repair, which is the same logic that applies to thymosin alpha-1 and immunity.
The practical obstacles are real. It is not available in the United States, so it is imported or compounded; it is porcine-derived, which matters for some people on dietary or religious grounds; and being a protein-derived mixture given by injection, allergic reaction is a genuine possibility rather than a boilerplate warning — which is why a test dose appears in the app’s own drawbacks list. This site names no vendor.
Anyone considering this for a diagnosed neurological condition should be having the conversation with the neurologist managing it, in a country where it is licensed if that is possible. Anything on the drawbacks list below belongs in the same conversation.
The dosing rows the app records
Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.
| Label | Amount | Route and frequency | Duration recorded |
|---|---|---|---|
| Cognitive Enhancement | 5-10ml IM or slow IV | Daily for 10-20 days, 2-4 cycles per year | 10-20 day cycles |
| TBI/Stroke Recovery | 10-30ml IV infusion | Daily — physician supervised | 4-6 weeks |
| Micro-dosing | 1-2ml IM | Every other day | 4-6 weeks |
What the app monitors alongside it
The panel below is the app’s own monitoring note for Cerebrolysin, verbatim. None of the analytes it names has a page here yet.
- Monitoring panel
- Cognitive self-assessment (memory, focus, processing speed). Mood tracking. No specific blood monitoring needed.
Drawbacks and risks the app records
From the app’s own entry, and the allergy item deserves more weight than its position suggests: this is an injected biological mixture, not a synthetic peptide.
- Injection only — IM or IV (no oral bioavailability)
- Porcine brain derived — not suitable for some
- Requires sourcing from countries where it's approved
- Not FDA approved in the United States
- Expensive per ampoule
- Rare allergic reactions possible — test dose recommended
Questions people actually ask
If there are 130 studies, why is it not approved in the US?
Because volume is not the same as persuasiveness. Independent systematic reviews, including Cochrane, have not found convincing evidence of benefit in stroke and have raised concerns about where the trials came from and how they were reported.
Does it work for cognitive enhancement?
That has not been studied. Every approved indication involves a damaged brain, and a neurotrophic agent plausibly has less to do where there is nothing to repair.
Why is there no half-life in the fact box?
Because it is a mixture of many peptides rather than one molecule, and the app holds no entry. A hydrolysate does not have a single half-life.
Is a test dose really necessary?
It is a porcine-derived protein mixture given by injection, so allergic reaction is a real possibility rather than a formality. That is what the app’s own drawbacks list is pointing at.
Where the load-bearing numbers come from
Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.
- Composition as a standardised porcine brain hydrolysate
- The product’s published manufacturing description
- Approvals and trial volume
- The approval string in the fact box is app.html’s own field; over a hundred clinical trials have been conducted
- Independent systematic review findings
- Cochrane reviews of cerebrolysin in acute ischaemic stroke and in dementia, which did not find evidence of benefit and raised reporting concerns
- Absence of pharmacokinetic data
- app.html holds no half-life or time-to-peak entry, which is why no such rows appear above
A ten to twenty day course repeated a few times a year is a schedule worth writing down. TherapyLog keeps the dates.
Save this dose to your log